Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform with the Addition of MOSS EOS for Early Onset Scoliosis Surgery
5.10.2026 12:00:00 EEST | Business Wire | Press release
Biedermann Motech, the prominent innovator in next generation spinal and extremity implant systems and procedural solutions, today announced the selective market introduction of the MOSS EOS® System for the treatment of children with severe early onset scoliosis.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005092768/en/
Early Onset Scoliosis is a rare pediatric disease where in certain cases surgical intervention can be indicated.2 Breaking new ground, Biedermann Motech will now introduce the world’s first MOSS EOS System featuring MOSS!MODULARITY™ to selective markets outside the U.S. The MOSS EOS System encompasses a modular platform of products and technologies for growth friendly pediatric spinal deformity surgery.
Prof. Dr. Heiko Koller from Germany, one of the innovators behind the MOSS EOS System, carried out the first surgeries. His feedback was that the versatility of the system offers surgeons a broad range of surgical options for the treatment of children with severe early onset scoliosis, and that the initial clinical outcomes were promising.
The MOSS!MODULARITY philosophy, an integral technology featured in all modern Biedermann thoracolumbar pedicle screw-based implant systems3, is based around the concept of providing an advanced modular workflow for posterior stabilisation and deformity correction. The modular workflow allows surgeons to place the headless bone screw shafts as a first step, without the tulip heads attached, and can offer several advantages over working with traditional pre-assembled pedicle screws, e.g.:
- Improved visualisation and access to the surgical working space;
- Precise decompression, decortication and osteotomies without any interference with polyaxial tulip heads;
- Increased surgical versatility, as surgeons can choose between different types of modular screw shafts and various tulip heads to be added to the screw shafts in-situ or on the back-table as and when required;
- In the context of treating patients with challenging deformities like early onset scoliosis, stiff adolescent scoliosis or adult deformity, staged surgery with modular screw shafts implanted at the first surgical stage can allow surgeons to further individualise surgical treatment.4
The MOSS EOS System featuring MOSS!MODULARITY incorporates proprietary technology licensed from intellectual property powerhouse and recognized innovation leader Biedermann Technologies GmbH & Co. KG and will be the first of its kind worldwide.
Biedermann Motech will showcase the MOSS EOS System featuring MOSS!MODULARITY at the upcoming Eurospine Meeting in Gothenburg, Sweden and will also arrange individual surgeon-to-surgeon meetings around the Annual Meeting of Scoliosis Research Society (SRS) in Sydney, Australia this week.
ABOUT BIEDERMANN MOTECH & BIEDERMANN TECHNOLOGIES:
CHALLENGING THE STATUS QUO. SINCE 1916™. Biedermann is a mid-sized, family-owned group of companies, whose roots go back to 1916 and is proudly celebrating its 110 year anniversary in 2026. Biedermann researches, develops, manufactures, and distributes high-end implant systems in collaboration with healthcare professionals, technology partners, scientific institutions, and specialized companies with the goal of achieving improved clinical outcomes. It is also owner and guardian of a substantial patent and technology portfolio for specialized orthopedic markets. For the last 34 years, Biedermann has successfully licensed numerous patents and related technologies to several key players in the orthopedic and neurosurgical field and established multiple new golden standards for spinal technologies.
For more information, please visit:
www.biedermann.com and www.biedermann-technologies.com
1 For details, please refer to the instruction for use
2 Orthopaedics and Trauma, Volume 35, Issue 6, 2021, Pages 336-346
3MOSS 100®, MOSS VRS®, MOSS VRS® MIS, MOSS EOS®. For details please refer to the instructions for use
4 The Spine Journal, Volume 24, Issue 9, Supplement, 2024, Page S29. Additional data on file at Biedermann Motech.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261005092768/en/
Contacts
transformation@biedermann.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FuzeBox AI Named Founding Co-Author of SPUR Coalition Technical Committee on Verifying AI Content Use5.10.2026 16:00:00 EEST | Press release
FuzeBox AI has been named by the SPUR Coalition, an international nonprofit of 37 news and media organizations, as one of four founding co-authors of its Evidence Profile Technical Committee, adopted Sept. 2, 2026, to draft an evidence profile for SPUR's Content Telemetry standard: a way for publishers to verify AI usage reports without depending on the reporting company's cooperation. Under SPUR's current standard, AI companies self-report their content use. A company that skips reporting leaves no record, and publishers can't check what they do receive. On July 10, 2026, FuzeBox proposed its Verified Provenance Telemetry Standard (VPTS): publishers seed content with detectable markers, then verify their appearance in AI outputs via an auditable ledger, with no change to SPUR's standard. Within 48 hours, three organizations filed related proposals: ProRata on usage magnitude, Encypher CEO Erik Svilich on the verification question FuzeBox raised, and LicenseFoundry on portable proof of
Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 15:02:00 EEST | Press release
Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty Texture Editwas designed to resonate with a global cultural beauty movement captivating the next gene
GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 15:00:00 EEST | Press release
GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005273717/en/ SOFIE Biosciences has 15 CMO sites across the U.S., manufacturing PET radiopharmaceutical products The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics
Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 14:24:00 EEST | Press release
Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking expertise with Solos' proprietary dealcoholization and patented aroma recovery technology. With 30 years of experience in producing alcohol-free sparkling wines, Henkell Fre
Croma-Pharma Expands Its Portfolio in Canada With saypha ® lips Lidocaine and Exprecell™5.10.2026 14:12:00 EEST | Press release
Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom